Lymphocytopenia as a prognostic marker for diffuse large B cell lymphomas

References

• Harris N L, Jaffe E S, Diebold J, Flandrin G, Muller-Hermelink H K, Vardiman J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 1999; 17: 3835–3849
   PubMed Web of Science ®Google Scholar
• Coiffier B. State-of-the-art therapeutics: diffuse large B-cell lymphoma. J Clin Oncol 2005; 23: 6387–6393
   PubMed Web of Science ®Google Scholar
• Fisher R I, Gaynor E R, Dahlberg S, Oken M M, Grogan T M, Mize E M, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993; 328: 1002–1006
   PubMed Web of Science ®Google Scholar
• Sehn L H, Donaldson J, Chhanabhai M, Fitzgerald C, Gill K, Klasa R, et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol 2005; 23: 5027–5033
   PubMed Web of Science ®Google Scholar
• Rueda A, Sabin P, Rifa J, Llanos M, Gomez-Codina J, Lobo F, et al. R-CHOP-14 in patients with diffuse large B-cell lymphoma younger than 70 years: a multicentre, prospective study. Hematol Oncol 2007, Sept 17, Epub ahead of print
   Web of Science ®Google Scholar
• Shipp M A, Harrington D P, Anderson J R, Armitage J O, Bonadonna G, Brittinger G, et al. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993; 329: 987–994
   PubMed Web of Science ®Google Scholar
• Hawkins C A, Collignon P, Adams D N, Bowden F J, Cook M C. Profound lymphopenia and bacteraemia. Intern Med J 2006; 36: 385–388
   PubMed Web of Science ®Google Scholar
• Heimann T M, Bolnick K, Aufses A H, Jr. Prognostic significance of severe preoperative lymphopenia in patients with Crohn's disease. Ann Surg 1986; 203: 132–135
   PubMed Web of Science ®Google Scholar
• Rudiger A, Burckhardt O A, Harpes P, Muller S A, Follath F. The relative lymphocyte count on hospital admission is a risk factor for long-term mortality in patients with acute heart failure. Am J Emerg Med 2006; 24: 451–454
   PubMed Web of Science ®Google Scholar
• Behl D, Porrata L F, Markovic S N, Letendre L, Pruthi R K, Hook C C, et al. Absolute lymphocyte count recovery after induction chemotherapy predicts superior survival in acute myelogenous leukemia. Leukemia 2006; 20: 29–34
   PubMed Web of Science ®Google Scholar
• Porrata L F, Gertz M A, Inwards D J, Litzow M R, Lacy M Q, Tefferi A, et al. Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation in multiple myeloma or non-Hodgkin lymphoma. Blood 2001; 98: 579–585
   PubMed Web of Science ®Google Scholar
• Siddiqui M, Ristow K, Markovic S N, Witzig T E, Habermann T M, Colgan J P, et al. Absolute lymphocyte count predicts overall survival in follicular lymphomas. Br J Haematol 2006; 134: 596–601
   PubMed Web of Science ®Google Scholar
• Behl D, Ristow K, Markovic S N, Witzig T E, Habermann T M, Colgan J P, et al. Absolute lymphocyte count predicts therapeutic efficacy of rituximab therapy in follicular lymphomas. Br J Haematol 2007; 137: 409–415
   PubMed Web of Science ®Google Scholar
• Bierman P J, Lynch J C, Bociek R G, Whalen V L, Kessinger A, Vose J M, et al. The International Prognostic Factors Project score for advanced Hodgkin's disease is useful for predicting outcome of autologous hematopoietic stem cell transplantation. Ann Oncol 2002; 13: 1370–1377
   PubMed Web of Science ®Google Scholar
• Kim D H, Baek J H, Chae Y S, Kim Y K, Kim H J, Park Y H, et al. Absolute lymphocyte counts predicts response to chemotherapy and survival in diffuse large B-cell lymphoma. Leukemia 2007; 21: 2227–2230
   PubMed Web of Science ®Google Scholar
• Smithers D W. Summary of papers delivered at the Conference on Staging in Hodgkin's Disease (Ann Arbor). Cancer Res 1971; 31: 1869–1870
   PubMed Web of Science ®Google Scholar
• Ray-Coquard I, Ghesquiere H, Bachelot T, Borg C, Biron P, Sebban C, et al. Identification of patients at risk for early death after conventional chemotherapy in solid tumours and lymphomas. Br J Cancer 2001; 85: 816–822
   PubMedGoogle Scholar
• Conlan M G, Bast M, Armitage J O, Weisenburger D D. Bone marrow involvement by non-Hodgkin's lymphoma: the clinical significance of morphologic discordance between the lymph node and bone marrow. Nebraska Lymphoma Study Group. J Clin Oncol 1990; 8: 1163–1172
   PubMed Web of Science ®Google Scholar
• Blay J Y, Chauvin F, Le Cesne A, Anglaret B, Bouhour D, Lasset C, et al. Early lymphopenia after cytotoxic chemotherapy as a risk factor for febrile neutropenia. J Clin Oncol 1996; 14: 636–643
   Google Scholar
• Lachenal F, Berger F, Ghesquieres H, Biron P, Hot A, Callet-Bauchu E, et al. Angioimmunoblastic T-cell lymphoma: clinical and laboratory features at diagnosis in 77 patients. Medicine (Baltimore) 2007; 86: 282–292
   PubMed Web of Science ®Google Scholar
• Bone R C. Sir Isaac Newton, sepsis, SIRS, and CARS. Crit Care Med 1996; 24: 1125–1128
   PubMed Web of Science ®Google Scholar
• Fauci A S. Mechanisms of corticosteroid action on lymphocyte subpopulations. I. Redistribution of circulating T and b lymphocytes to the bone marrow. Immunology 1975; 28: 669–680
   PubMed Web of Science ®Google Scholar
• Treacy M, Lai L, Costello C, Clark A. Peripheral blood and bone marrow abnormalities in patients with HIV related disease. Br J Haematol 1987; 65: 289–294
   PubMed Web of Science ®Google Scholar
• Stebbing J, Sawleshwarkar S, Michailidis C, Jones R, Bower M, Mandalia S, et al. Assessment of the efficacy of total lymphocyte counts as predictors of AIDS defining infections in HIV-1 infected people. Postgrad Med J 2005; 81: 586–588
   PubMed Web of Science ®Google Scholar
• Kim R, Emi M, Tanabe K, Arihiro K. Tumor-driven evolution of immunosuppressive networks during malignant progression. Cancer Res 2006; 66: 5527–5536
   PubMed Web of Science ®Google Scholar
• Choi C W, Sung H J, Park K H, Yoon S Y, Kim S J, Oh S C, et al. Early lymphopenia as a risk factor for chemotherapy-induced febrile neutropenia. Am J Hematol 2003; 73: 263–266
   PubMed Web of Science ®Google Scholar
• Ray-Coquard I, Borg C, Bachelot T, Sebban C, Philip I, Clapisson G, et al. Baseline and early lymphopenia predict for the risk of febrile neutropenia after chemotherapy. Br J Cancer 2003; 88: 181–186
   PubMed Web of Science ®Google Scholar
• Reff M E, Carner K, Chambers K S, Chinn P C, Leonard J E, Raab R, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994; 83: 435–445
   PubMed Web of Science ®Google Scholar
• Cartron G, Watier H, Golay J, Solal-Celigny P. From the bench to the bedside: ways to improve rituximab efficacy. Blood 2004; 104: 2635–2642
   PubMed Web of Science ®Google Scholar